Destiny Pharma targets growth as anti-infection treatments return to prominence

0
15
  • Destiny Pharma’s China partner begins programme to develop new skin infection product
  • Destiny Pharma’s hail ‘win win deal’ as China partner begins programme with their skin product
Destiny Pharma PLC - Destiny Pharma targets growth as anti-infection treatments rise to prominence

Quick facts: Destiny Pharma PLC

Follow

View company profile

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is reporting results in Q1 2021 from a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

27 Sep 2021

() said its partner in China is to launch a new programme aimed at delivering a new product using Destiny’s XF-73 to target the prevention and treatment of superficial skin infections caused by bacteria.

() Ltd (CMS), the AIM-listed company’s regional partner and also an investor with a 5.76% stake, is establishing a programme in China to focus on developing a novel product in the local regulatory environment.

CMS will lead, manage and fund the programme, with Destiny contributing scientific advice as required through a steering committee to the expert dermatology team at CMS.

Destiny Pharma noted that CMS already has a portfolio of dermatology assets and therefore an expert understanding of the market and its requirements through its existing sales and marketing infrastructure.

Read more

09 Sep 2021

() hailed the progress made with its two lead assets.

In an update alongside interim results, it said a phase III evaluation of the NTCD-M3 programme targeting C. difficile ( ()) is on track to begin in the second half of next year.

Read more

02 Aug 2021

() has unveiled what it described as “strong data” from its recent Phase 2b clinical trial of its XF-73 nasal gel.

The additional data showed that cardiac surgery patients receiving XF-73 nasal gel exhibited a valuable, sustained nasal reduction of Staphylococcus aureus (commonly referred to as “staph) bacteria after wound closure.

Read more

28 Sep 2021

() () Neil Clark talks to Proactive London about their partner in China, Hong Kong listed () () Ltd (CMS) launching a new programme aimed at delivering a new product using Destiny’s XF-73.

Their aim differs to Destiny as Neil explains, targeting the prevention and treatment of superficial skin infections caused by bacteria. The firm is also an investor with an over 10% stake.

They’ll be running their own programme, but both parties will benefit by sharing the data and developments made by both parties. CMS will lead, manage and fund the programme, with Destiny contributing scientific advice as required through a steering committee to the expert dermatology team at CMS.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Destiny Pharma’s hail ‘win win deal’ as China partner begins programme with…

Destiny Pharma PLC (AIM:DEST) (AIM:DEST) Neil Clark talks to Proactive London about their partner in China, Hong Kong listed China Medical System Holdings (HKG:0867) (HKG:0867) Ltd (CMS) launching a new programme aimed at delivering a new product using Destiny’s XF-73.

Their aim differs to…

16 hours, 24 minutes ago

6 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here